Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
IMGN's Cash to Debt is ranked higher than
95% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. IMGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
IMGN' s 10-Year Cash to Debt Range
Min: 0.39   Max: 50356.33
Current: No Debt

0.39
50356.33
Equity to Asset 0.45
IMGN's Equity to Asset is ranked lower than
74% of the 599 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IMGN: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
IMGN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.95
Current: 0.45

0.27
0.95
Interest Coverage No Debt
IMGN's Interest Coverage is ranked higher than
91% of the 382 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMGN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IMGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -0.85
M-Score: 10.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -71.01
IMGN's Operating margin (%) is ranked higher than
51% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. IMGN: -71.01 )
Ranked among companies with meaningful Operating margin (%) only.
IMGN' s 10-Year Operating margin (%) Range
Min: -1560   Max: -6.81
Current: -71.01

-1560
-6.81
Net-margin (%) -72.15
IMGN's Net-margin (%) is ranked higher than
50% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. IMGN: -72.15 )
Ranked among companies with meaningful Net-margin (%) only.
IMGN' s 10-Year Net-margin (%) Range
Min: -1520   Max: -2.13
Current: -72.15

-1520
-2.13
ROE (%) -76.76
IMGN's ROE (%) is ranked lower than
75% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. IMGN: -76.76 )
Ranked among companies with meaningful ROE (%) only.
IMGN' s 10-Year ROE (%) Range
Min: -172.73   Max: -2.3
Current: -76.76

-172.73
-2.3
ROA (%) -37.47
IMGN's ROA (%) is ranked lower than
63% of the 835 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. IMGN: -37.47 )
Ranked among companies with meaningful ROA (%) only.
IMGN' s 10-Year ROA (%) Range
Min: -124.59   Max: -1.79
Current: -37.47

-124.59
-1.79
ROC (Joel Greenblatt) (%) -400.07
IMGN's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -353.07 vs. IMGN: -400.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -666.37   Max: -48.97
Current: -400.07

-666.37
-48.97
Revenue Growth (3Y)(%) 35.70
IMGN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. IMGN: 35.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IMGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -36.1   Max: 133.1
Current: 35.7

-36.1
133.1
EBITDA Growth (3Y)(%) -0.80
IMGN's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. IMGN: -0.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IMGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -71.2   Max: 282.6
Current: -0.8

-71.2
282.6
EPS Growth (3Y)(%) -0.80
IMGN's EPS Growth (3Y)(%) is ranked higher than
57% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. IMGN: -0.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IMGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -75.7   Max: 263.4
Current: -0.8

-75.7
263.4
» IMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

IMGN Guru Trades in Q2 2014

Jim Simons 415,440 sh (New)
PRIMECAP Management 11,922,396 sh (-5.94%)
» More
Q3 2014

IMGN Guru Trades in Q3 2014

PRIMECAP Management 11,918,396 sh (-0.03%)
Jim Simons 370,446 sh (-10.83%)
» More
Q4 2014

IMGN Guru Trades in Q4 2014

PRIMECAP Management 12,127,073 sh (+1.75%)
Jim Simons 162,840 sh (-56.04%)
» More
Q1 2015

IMGN Guru Trades in Q1 2015

PRIMECAP Management 12,609,150 sh (+3.98%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.10
IMGN's P/B is ranked lower than
88% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. IMGN: 13.10 )
Ranked among companies with meaningful P/B only.
IMGN' s 10-Year P/B Range
Min: 1.68   Max: 16.54
Current: 13.1

1.68
16.54
P/S 9.90
IMGN's P/S is ranked higher than
57% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.45 vs. IMGN: 9.90 )
Ranked among companies with meaningful P/S only.
IMGN' s 10-Year P/S Range
Min: 2.83   Max: 97.63
Current: 9.9

2.83
97.63
Current Ratio 5.22
IMGN's Current Ratio is ranked higher than
56% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. IMGN: 5.22 )
Ranked among companies with meaningful Current Ratio only.
IMGN' s 10-Year Current Ratio Range
Min: 0.51   Max: 60.86
Current: 5.22

0.51
60.86
Quick Ratio 5.10
IMGN's Quick Ratio is ranked higher than
57% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. IMGN: 5.10 )
Ranked among companies with meaningful Quick Ratio only.
IMGN' s 10-Year Quick Ratio Range
Min: 0.51   Max: 60.86
Current: 5.1

0.51
60.86
Days Sales Outstanding 3.50
IMGN's Days Sales Outstanding is ranked higher than
96% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. IMGN: 3.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMGN' s 10-Year Days Sales Outstanding Range
Min: 1.53   Max: 730
Current: 3.5

1.53
730

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.40
IMGN's Price/Net Cash is ranked lower than
62% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. IMGN: 20.40 )
Ranked among companies with meaningful Price/Net Cash only.
IMGN' s 10-Year Price/Net Cash Range
Min: 0.9   Max: 179
Current: 20.4

0.9
179
Price/Net Current Asset Value 19.50
IMGN's Price/Net Current Asset Value is ranked lower than
61% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. IMGN: 19.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IMGN' s 10-Year Price/Net Current Asset Value Range
Min: 0.85   Max: 78.15
Current: 19.5

0.85
78.15
Price/Tangible Book 13.00
IMGN's Price/Tangible Book is ranked lower than
82% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. IMGN: 13.00 )
Ranked among companies with meaningful Price/Tangible Book only.
IMGN' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 40
Current: 13

0.81
40
Price/Median PS Value 0.70
IMGN's Price/Median PS Value is ranked higher than
83% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. IMGN: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
IMGN' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 12.5
Current: 0.7

0.24
12.5
Earnings Yield (Greenblatt) -8.10
IMGN's Earnings Yield (Greenblatt) is ranked lower than
55% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.60 vs. IMGN: -8.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
IMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -15.4   Max: 0
Current: -8.1

-15.4
0

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 98 130 65 59
EPS($) -0.66 -0.75 -1.35 -1.49
EPS without NRI($) -0.66 -0.75 -1.35 -1.49

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IMU.Germany,
Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: IMGN853, IMGN289, and IMGN529. It's IMGN853 product candidate is used for the treatment of ovarian cancer, endometrial cancer, and potentially other cancers that highly express folate receptor a, or FRa. It's EGFR-targeting ADC, IMGN289, is used for the treatment of cancers that highly express EGFR which include squamous cell carcinoma of the head and neck, or SCCHN, and types of non-small cell lung cancer (NSCLC), including both squamous cell and non-squamous cell NSCLCs. It's IMGN529 ADC is used for the treatment of cancers that highly express CD37, such as non-Hodgkin lymphoma, or NHL, and chronic lymphocytic leukemia. The Company's main competitors include Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. In addition to regulations in the U.S., the company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.
» More Articles for NAS:IMGN

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) Surge on Jan 31 2015 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
IMMUNOGEN INC Files SEC form 8-K, Other Events May 21 2015
IMMUNOGEN INC Financials May 15 2015
The 5 Winners and Losers From ASCO Presentations May 14 2015
ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting May 13 2015
10-Q for ImmunoGen, Inc. May 11 2015
IMMUNOGEN INC Files SEC form 10-Q, Quarterly Report May 08 2015
Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks May 06 2015
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences May 04 2015
ImmunoGen skids after disclosing drug development setbacks Apr 27 2015
ImmunoGen skids after disclosing drug development setbacks Apr 27 2015
ImmunoGen Inc Earnings Call scheduled for 8:00 am ET today Apr 24 2015
Q3 2015 ImmunoGen Inc Earnings Release - Before Market Open Apr 24 2015
ImmunoGen reports 3Q loss Apr 24 2015
ImmunoGen reports 3Q loss Apr 24 2015
IMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 24 2015
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2015 Financial Results Apr 24 2015
Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog Apr 22 2015
Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog Apr 21 2015
Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog Apr 21 2015
Will Eli Lilly (LLY) Beat Earnings in 1Q Despite Generics? - Analyst Blog Apr 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK